Pharmaceutical formulation for the treatment of diabetes mellitus

Abstract From the Canadian patent

Pharmaceutical formulation containing at least one insulin derivative modified with a base in position B31 of the insulin B chain and having an isoelectric point between 5.8 and 8.5 and/or at least one of its physiologically tolerated salts in a pharmaceutically acceptable excipient and a relatively high zinc ion content in the range from above 1 µg to about 200 µg of zing/IU. The preferred insulin derivative modified with a base for this pharmaceutical formulation is human insulin-B31- Arg-OH and human insulin-B31-Arg-B32-Arg-OH. The formulation is used for the treatment of diabetes mellitus; it has a particularly favorable action profile.